Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.54 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5013543 | 0.82 | PTGS2 (0.52) | PTGS2ALDH1A1MEN1KMT2AAKT1 | |
| SCHEMBL5013551 | 0.81 | PTGER1 (0.39) | PTGS2PTGER1KDM4EALDH1A1KMT2A | |
| SCHEMBL7239242 | 0.75 | SMN1; SMN2 (0.42) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL7242414 | 0.74 | SMN1; SMN2 (0.42) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL7836982 | 0.71 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL3247750 | 0.71 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL3245733 | 0.70 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL5015641 | 0.70 | PTGS2 (0.43) | PTGS2PTGER1PTGS1ALDH1A1MAPT | |
| SCHEMBL10175287 | 0.70 | GABRA2 (0.42) | PTGS2KDM4EALDH1A1 | |
| SCHEMBL5012213 | 0.69 | TP53 (0.50) | KDM4EALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-09 | — | — | US | claimed |
| EP-1773331-A1 | IMIDAZOLE AND THIAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-04-18 | — | — | EP | claimed |
| WO-2006008556-A1 | IMIDAZOLE AND THIAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2006-01-26 | — | — | WO | claimed |
| WO-2008127613-A1 | NEW PHARMACEUTICAL COMPOSITIONS | SCYNEXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | SCYNEXIS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-09 | — | — | US | disclosed |
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-09 | — | — | US | disclosed |
| EP-1773331-A1 | IMIDAZOLE AND THIAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006008556-A1 | IMIDAZOLE AND THIAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | NSUN2, TPMT, EIF5B | PTGS2 3442/4885PTGER1 3296/4885PTGS1 3116/4885 |
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | IRF3, HAVCR2, ZC3HAV1 | PTGS2 1565/4885PTGER1 1858/4885PTGS1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.